Institution · Santhera Pharmaceuticals (Switzerland)

Most cited papers from Santhera Pharmaceuticals (Switzerland)

Santhera Pharmaceuticals (Switzerland)

What are the most cited papers from Santhera Pharmaceuticals (Switzerland)?

The most cited paper from Santhera Pharmaceuticals (Switzerland) is "A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy" (Thomas Klopstock, Patrick Yu‐Wai‐Man, Konstantinos A. Dimitriadis et al., 2011), with 579 citations. Next come "Diagnosis and treatment of Friedreich ataxia: a European perspective" (263) and "A Phase 3, Double-blind, Placebo-Controlled Trial of Idebenone in Friedreich Ataxia" (226).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 19 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy Thomas Klopstock, Patrick Yu‐Wai‐Man, Konstantinos A. Dimitriadis et al. · Brain Open access	23 Jul 2011	579
2	Diagnosis and treatment of Friedreich ataxia: a European perspective Jörg Bernhard Schulz, Sylvia Boesch, Katrin Bürk et al. · Nature Reviews Neurology Review	Apr 2009	263
3	A Phase 3, Double-blind, Placebo-Controlled Trial of Idebenone in Friedreich Ataxia David R. Lynch, Susan Perlman, Thomas W. Meier · Archives of Neurology Open access	Aug 2010	226
4	NQO1-Dependent Redox Cycling of Idebenone: Effects on Cellular Redox Potential and Energy Levels Roman H. Haefeli, Michael A. Erb, Anja C. Gemperli et al. · PLoS ONE Open access	31 Mar 2011	188
5	Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial Gunnar Buyse, Thomas Voït, Ulrike Schara et al. · The Lancet Open access	20 Apr 2015	186
6	Mammalian animal models for Duchenne muscular dystrophy Raffaella Willmann, Stefanie Possekel, Judith Dubach‐Powell et al. · Neuromuscular Disorders	13 Feb 2009	186
7	Discovery of Riociguat (BAY 63‐2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension Joachim Mittendorf, Stefan Weigand, Cristina Alonso‐Alija et al. · ChemMedChem	4 Mar 2009	185
8	The Heart in Friedreich Ataxia Frank Weidemann, Christian Rummey, Bart H. Bijnens et al. · Circulation Open access	29 Feb 2012	158
9	Characterization of pulmonary function in Duchenne Muscular Dystrophy Oscar Henry Mayer, Richard S. Finkel, Christian Rummey et al. · Pediatric Pulmonology Open access	9 Mar 2015	156
10	Idebenone in Friedreich ataxia cardiomyopathy—results from a 6-month phase III study (IONIA) Sarah J. Lagedrost, Martin St. John Sutton, Meryl S. Cohen et al. · American Heart Journal	Feb 2011	144
11	Idebenone Protects against Retinal Damage and Loss of Vision in a Mouse Model of Leber’s Hereditary Optic Neuropathy Fabrice D. Heitz, Michael A. Erb, Corinne Anklin et al. · PLoS ONE Open access	18 Sep 2012	110
12	Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized placebo-controlled trial Gunnar Buyse, Nathalie Goemans, M. van den Hauwe et al. · Neuromuscular Disorders	14 Apr 2011	104
13	Meta-analysis of the prevalence of Leber hereditary optic neuropathy mtDNA mutations in Europe Barbara MASCIALINO, Mika Leinonen, Thomas W. Meier · European Journal of Ophthalmology Review	16 Sep 2011	103
14	Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance Gunnar Buyse, Gerry Van der Mieren, Michael A. Erb et al. · European Heart Journal Open access	28 Jul 2008	101
15	Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study Thomas W. Meier, Susan Perlman, Christian Rummey et al. · Journal of Neurology	21 Jul 2011	97
16	Pharmacological characterization and CNS effects of a novel highly selectiveα2C‐adrenoceptor antagonist JP‐1302 Jukka Sallinen, Iisa P. J. Höglund, Mia Engström et al. · British Journal of Pharmacology Open access	15 Jan 2007	96
17	Features of Idebenone and Related Short-Chain Quinones that Rescue ATP Levels under Conditions of Impaired Mitochondrial Complex I Michael A. Erb, Barbara Hoffmann-Enger, H. Deppe et al. · PLoS ONE Open access	27 Apr 2012	95
18	Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy Jean Kit-Wah Mah et al. · JAMA Network Open Open access143 authors	25 Jan 2022	92
19	Omigapil Ameliorates the Pathology of Muscle Dystrophy Caused by Laminin-α2 Deficiency Michael A. Erb, Sarina Meinen, Patrizia Barzaghi et al. · Journal of Pharmacology and Experimental Therapeutics	17 Sep 2009	88
20	Idebenone: An emerging therapy for Friedreich ataxia Thomas W. Meier, Gunnar Buyse · Journal of Neurology	Mar 2009	85
21	Asymmetric Recruitment of Dynein to Spindle Poles and Microtubules Promotes Proper Spindle Orientation in Yeast Sandrine Grava, Florian Schaerer, Mahamadou Faty et al. · Developmental Cell Open access	Apr 2006	85
22	Enhancing translation: Guidelines for standard pre-clinical experiments in mdx mice Raffaella Willmann, Annamaria De Luca, Michael G Benatar et al. · Neuromuscular Disorders Open access	7 Jul 2011	83
23	Effects of Idebenone on Color Vision in Patients With Leber Hereditary Optic Neuropathy Guenther Rudolph, Konstantinos A. Dimitriadis, Boriana Büchner et al. · Journal of Neuro-Ophthalmology Open access	22 Dec 2012	79
24	Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site Christian Rummey, Günther Metz · Proteins Structure Function and Bioinformatics Open access	26 Oct 2006	68
25	Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy Craig M. McDonald et al. · Neuromuscular Disorders Open access	12 May 2016	63
26	Pharmacokinetic evaluation of idebenone Claudia Becker, Katharine Bray‐French, Jürgen Drewe · Expert Opinion on Drug Metabolism & Toxicology	19 Oct 2010	61
27	Characterization of pulmonary function in 10–18 year old patients with Duchenne muscular dystrophy Thomas W. Meier et al. · Neuromuscular Disorders Open access	7 Jan 2017	59
28	Rating disease progression of Friedreich’s ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database Günther Metz, Nicholas J. Coppard, Jonathon M. Cooper et al. · Brain Open access	2013	57
29	Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy Gunnar Buyse, Nathalie Goemans, M. van den Hauwe et al. · Pediatric Pulmonology	5 Nov 2012	57
30	The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia Robert Dallmann et al. · Journal of Cachexia Sarcopenia and Muscle Open access	27 Aug 2011	56
31	Near‐Infrared Light Triggered‐Release in Deep Brain Regions Using Ultra‐photosensitive Nanovesicles Hejian Xiong, Xiuying Li, Peiyuan Kang et al. · Angewandte Chemie International Edition Open access	2 Mar 2020	55
32	Substituted Cyclobutenes, Their Preparation, and Their Versatility in Synthesis Noe͏̈lle Gauvry, Cyrille Lescop, F. Huet · European Journal of Organic Chemistry	24 Aug 2006	54
33	Effect of calpain and proteasome inhibition on Ca 2+ ‐dependent proteolysis and muscle histopathology in the mdx mouse Alexandre Briguet, Michael A. Erb, I. Courdier-Fruh et al. · The FASEB Journal	26 Aug 2008	53
34	Manipulating placebo analgesia and nocebo hyperalgesia by changing brain excitability Yiheng Tu, Georgia Wilson, Joan Albert Camprodon et al. · Proceedings of the National Academy of Sciences Open access	3 May 2021	52
35	Orally Available Selective Melanocortin-4 Receptor Antagonists Stimulate Food Intake and Reduce Cancer-Induced Cachexia in Mice Philipp Weyermann, Robert Dallmann, Josef P. Magyar et al. · PLoS ONE Open access	18 Mar 2009	51
36	Apoptosis inhibitors and mini‐agrin have additive benefits in congenital muscular dystrophy mice Sarina Meinen, Shuo Liang Lin, Raphael Thurnherr et al. · EMBO Molecular Medicine Open access	15 Jun 2011	51
37	Pharmacokinetics and metabolism of idebenone in healthy male subjects Michael Bodmer, Pierre Vankan, Manfred Dreier et al. · European Journal of Clinical Pharmacology	5 Jan 2009	49
38	Should ambulatory appendectomy become the standard treatment for acute appendicitis? Benoit Gignoux, Marie‐Cécile Blanchet, Thomas Lanz et al. · World Journal of Emergency Surgery Open access	28 Jun 2018	48
39	Activation of Muscle-specific Receptor Tyrosine Kinase and Binding to Dystroglycan Are Regulated by Alternative mRNA Splicing of Agrin Patrick Scotton, Dorothée Bleckmann, Michael Stebler et al. · Journal of Biological Chemistry Open access	30 Sep 2006	47
40	Business development with electronic commerce: refinement and repositioning Niklas Aldin, Per‐Olof Brehmer, Anders Johansson · Business Process Management Journal	Feb 2004	45
41	Muscle-wide secretion of a miniaturized form of neural agrin rescues focal neuromuscular innervation in agrin mutant mice Shuo Liang Lin, Marcin Maj, Gabriela Bezáková et al. · Proceedings of the National Academy of Sciences Open access	6 Aug 2008	45
42	Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy Gunnar Buyse, Thomas Voït, Ulrike Schara et al. · Pediatric Pulmonology Open access	29 Aug 2016	44
43	Loss of skeletal muscle strength by ablation of the sarcoplasmic reticulum protein JP45 Osvaldo Delbono, Jinyu Xia, Susan Treves et al. · Proceedings of the National Academy of Sciences Open access	5 Dec 2007	42
44	The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates Tom H. Johnston, Susan Helen Fox, Matthew Piggott et al. · Movement Disorders	7 Sep 2010	40
45	Design and Synthesis of Potent and Selective Azaindole‐Based Rho Kinase (ROCK) Inhibitors Hartmut Schirok, Raimund Kast, Santiago Figueroa‐Pérez et al. · ChemMedChem Open access	30 Oct 2008	39
46	Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy Laurent Servais, Chiara S. M. Straathof, Ulrike Schara et al. · Neuromuscular Disorders Open access	4 Nov 2019	38
47	Novel cell-penetrating α-keto-amide calpain inhibitors as potential treatment for muscular dystrophy Cyrille Lescop, Holger Herzner, Hervé Siendt et al. · Bioorganic & Medicinal Chemistry Letters Open access	27 Sep 2005	37
48	Different routes of administration in chronic migraine prevention lead to different placebo responses: a meta-analysis Diego Belandrino Swerts, Fabrizio Benedetti, Mário Fernando Prieto Peres · Pain Review	14 Jun 2021	35
49	Efficacy of Idebenone to Preserve Respiratory Function above Clinically Meaningful Thresholds for Forced Vital Capacity (FVC) in Patients with Duchenne Muscular Dystrophy Oscar Henry Mayer, Mika Leinonen, Christian Rummey et al. · Journal of Neuromuscular Diseases Open access	29 Aug 2017	35
50	Idebenone does not inhibit disability progression in primary progressive MS Peter F. Kosa, Tianxia Wu, Jonathan A. Phillips et al. · Multiple Sclerosis and Related Disorders Open access	5 Aug 2020	32

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.